ADAM8: a new therapeutic target for asthma.
| Autor: | Knolle MD; Brigham and Women's Hospital, Harvard Medical School, Division of Pulmonary and Critical Care Medicine, 905 Thorn Building, 75 Francis Street, Boston, MA 02115, USA., Owen CA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on therapeutic targets [Expert Opin Ther Targets] 2009 May; Vol. 13 (5), pp. 523-40. |
| DOI: | 10.1517/14728220902889788 |
| Abstrakt: | Background: A proteinase with a disintegrin and a metalloproteinase domain-8 (ADAM8) has been linked to asthma. Objective: To explore whether ADAM8 is a therapeutic target for asthma. Methods: We reviewed literature on ADAM8's function and expression and activities in lungs of humans and mice with allergic airway inflammation (AAI). We used these data to generate hypotheses about the contributions of ADAM8 to asthma pathogenesis. Conclusions: ADAM8 levels are increased in airway epithelium and airway inflammatory cells in mice with AAI and human asthma patients. Data from murine models of AAI indicate that ADAM8 dampens airway inflammation. It is not clear whether ADAM8 contributes directly to structural remodeling in asthmatic airways. Additional studies are required to validate ADAM8 as a therapeutic target for asthma. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|